Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma

Document Type

Article

Publication Date

4-1-2021

Abstract

The development of resistance to trastuzumab in HER2-positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.

Keywords

Dual HER2, Gastroesophageal cancer, HER2, Lapatinib, Trastuzumab

Publication Title

Clinical Case Reports

Divisions

oncology,medicinedept

Volume

9

Issue

4

Publisher

Wiley

This document is currently not available here.

Share

COinS